Investment analysts at Cantor Fitzgerald raised their target price on shares of Salix Pharmaceuticals (NASDAQ: SLXP) from $60.00 to $63.00 in a note issued to investors on Friday. The firm currently has a “buy” rating on the stock.

Salix Pharmaceuticals opened at 48.85 on Friday. Salix Pharmaceuticals has a 1-year low of $37.52 and a 1-year high of $55.99. The stock’s 50-day moving average is currently $47.81. The company has a market cap of $2.874 billion and a price-to-earnings ratio of 37.90.

Salix Pharmaceuticals last issued its quarterly earnings data on Thursday, February 28th. The company reported $0.81 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.78 by $0.03. The company had revenue of $198.17 million for the quarter, compared to the consensus estimate of $199.41 million. During the same quarter in the prior year, the company posted $1.18 earnings per share. The company’s quarterly revenue was up 27.7% on a year-over-year basis. Salix Pharmaceuticals has set its FY13 guidance at approx $3.37 EPS. On average, analysts predict that Salix Pharmaceuticals will post $3.19 earnings per share for the current fiscal year.

Other equities research analysts have also recently issued reports about the stock. Analysts at Janney Montgomery Scott initiated coverage on shares of Salix Pharmaceuticals in a research note to investors on Thursday, January 31st. They set a “buy” rating and a $55.00 price target on the stock. Separately, analysts at RBC Capital initiated coverage on shares of Salix Pharmaceuticals in a research note to investors on Friday, January 11th. They set an “outperform” rating and a $53.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Salix Pharmaceuticals in a research note to investors on Friday, January 4th. They now have a $46.00 price target on the stock.

Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal diseases, which are those affecting the digestive tract.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.